Hyperfine, Inc.

HYPR ·Healthcare, Medical Devices, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Revenue $13.6M $12.9M $11.0M $6.8M $1.5M $294.0K
Cost of Revenue $6.8M $7.0M $6.3M $5.9M $2.7M $771.0K
Gross Profit $6.8M $5.9M $4.8M $907.0K $-1.2M $-477.0K
Gross Margin 49.8% 45.7% 43.1% 13.3% -78.0% -162.2%
Operating Expenses
Research & Development $17.5M $22.5M $22.5M $28.2M $25.8M $14.6M
SG&A Expense $16.3M $17.5M $20.3M $32.4M $27.5M $5.9M
Operating Income $-37.1M $-43.2M $-48.1M $-73.9M $-64.9M $-23.5M
Operating Margin -273.4% -335.3% -436.1% -1,084.2% -4,336.1% -7,990.1%
Interest Expense
Pretax Income $-35.6M $-40.7M $-44.2M $-73.2M $-64.9M $-23.4M
Income Tax Expense $0 $0 $0 $0 $0
Net Income $-35.6M $-40.7M $-44.2M $-44.2M $-64.9M $-23.4M
Net Margin -262.3% -315.9% -401.0% -649.2% -4,335.0% -7,968.4%
EPS (Basic) $-0.43 $-0.56 $-0.62 $-1.04 $-0.92 $-0.81
EPS (Diluted) $-0.43 $-0.56 $-0.62 $-1.04 $-0.92 $-0.81
Shares Outstanding (Basic) 81.8M 72.4M 71.3M 70.4M 70.1M
Shares Outstanding (Diluted) 81.8M 72.4M 71.3M 70.4M 70.1M
Dividends Per Share